Cowen and Company’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Cowen and Company’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-25,000	Closed	-$66.5K	–	800
2024 Q1	$66.5K	Buy	+25,000	New	+$61.9K	﹤0.01%	324

Cowen and Company's KNTE Position: Q2 2024 in Review

Cowen and Company sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 25,000 shares — an estimated $66.5K sold.

Cowen and Company first reported a position in KNTE in Q1 2024 and held it in 1 quarter. The position peaked at $66.5K in Q1 2024. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

Cowen and Company reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Cowen and Company sold 25,000 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $66.5K.
Cowen and Company first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2024 and held it in 1 quarter.
Cowen and Company's Kinnate Biopharma Inc. Common Stock position peaked at $66.5K in Q1 2024.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Cowen and Company's 13F filing for Q2 2024, filed 7 Aug 2024.